AI Engines For more Details: Perplexity Kagi Labs You
Relief of Constipation: Bisacodyl works by stimulating the muscles in the intestines, which increases the movement of stool through the bowels. This helps to relieve constipation and promote regular bowel movements.
Treatment of Bowel Irregularities: It is used to treat occasional constipation and to help patients with certain bowel irregularities, such as those caused by certain medications or medical conditions.
Preparation for Medical Procedures: Bisacodyl is sometimes used to prepare the bowel for medical procedures such as colonoscopies or bowel surgery. It helps to empty the bowel completely, allowing for better visualization during the procedure.
Onset of Action: Bisacodyl usually produces a bowel movement within 6 to 12 hours after taking the medication. It is often taken at bedtime to produce a bowel movement the following morning.
Administration: Bisacodyl is available in various forms, including oral tablets, suppositories, and enemas. The choice of formulation depends on the individual's preferences, medical condition, and the desired onset of action.
Side Effects: Common side effects of bisacodyl include abdominal discomfort, cramping, nausea, and diarrhea. These side effects are usually mild and temporary. However, if they persist or worsen, it's important to consult a healthcare provider.
Dehydration: Excessive use of stimulant laxatives like bisacodyl can lead to dehydration, electrolyte imbalances, and dependence on laxatives for bowel movements. It's essential to use bisacodyl as directed and not to exceed the recommended dosage.
Not for Long-Term Use: Bisacodyl is generally not recommended for long-term use, as prolonged use of stimulant laxatives can lead to bowel dependence and other complications. It's important to address underlying causes of constipation and to make lifestyle changes to promote regular bowel movements.
Contraindications: Bisacodyl should not be used by individuals with certain medical conditions, including intestinal blockage, severe abdominal pain, appendicitis, inflammatory bowel disease, or rectal bleeding. It's important to consult a healthcare provider before using bisacodyl, especially if you have any underlying medical conditions or are taking other medications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 1.8 | 0.1 | 17 |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.9 | |
| Allergies | 0.7 | 0.4 | 0.75 |
| Allergy to milk products | 0.9 | 0.2 | 3.5 |
| Alzheimer's disease | 1.7 | 0.9 | 0.89 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.5 | 0 |
| Ankylosing spondylitis | 0.9 | 0.9 | 0 |
| Anorexia Nervosa | 0.4 | -0.4 | |
| Antiphospholipid syndrome (APS) | 0.5 | 0.1 | 4 |
| Asthma | 0.1 | 0.2 | -1 |
| Atherosclerosis | 0.4 | 0.1 | 3 |
| Atrial fibrillation | 0.4 | 0.7 | -0.75 |
| Autism | 1.8 | 1.2 | 0.5 |
| Barrett esophagus cancer | 0.3 | 0 | 0 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 0.6 | 0.2 | 2 |
| Brain Trauma | 0.2 | -0.2 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.7 | 0.4 | 0.75 |
| Cerebral Palsy | 0.1 | 0.3 | -2 |
| Chronic Fatigue Syndrome | 2.5 | 0.5 | 4 |
| Chronic Kidney Disease | 0.8 | 0.1 | 7 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.1 | 3 |
| Chronic Urticaria (Hives) | 0.8 | 0.4 | 1 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.1 | 6 |
| Colorectal Cancer | 2.1 | 2.1 | |
| Constipation | 0.5 | 0.5 | |
| Coronary artery disease | 0.4 | 0.1 | 3 |
| COVID-19 | 3.4 | 3.2 | 0.06 |
| Crohn's Disease | 3.4 | 0.9 | 2.78 |
| cystic fibrosis | 0.7 | 0.2 | 2.5 |
| deep vein thrombosis | 0.7 | 0.1 | 6 |
| Depression | 3 | 1 | 2 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0.6 | 0.4 | 0.5 |
| Endometriosis | 1 | 0.1 | 9 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 1 | 0.2 | 4 |
| Fibromyalgia | 0.7 | 1.5 | -1.14 |
| Functional constipation / chronic idiopathic constipation | 1.9 | 1.2 | 0.58 |
| gallstone disease (gsd) | 0.4 | 0.3 | 0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0 | 0 |
| Generalized anxiety disorder | 1.3 | 0.4 | 2.25 |
| giant cell arteritis | 0.1 | -0.1 | |
| Glioblastoma | 0 | 0 | |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 0.2 | 0.2 | |
| Halitosis | 0.5 | 0 | 0 |
| Hashimoto's thyroiditis | 0.2 | 0.3 | -0.5 |
| Hidradenitis Suppurativa | 0.4 | 0.4 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.7 | 0.2 | 2.5 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.2 | 0.2 | 0 |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.6 | 0.6 | 0 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 2 | -2 | |
| Inflammatory Bowel Disease | 2.1 | 1 | 1.1 |
| Insomnia | 0.3 | 0.2 | 0.5 |
| Intelligence | 1 | 0.2 | 4 |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1.5 | 1.7 | -0.13 |
| Liver Cirrhosis | 1.1 | 0.6 | 0.83 |
| Long COVID | 2.4 | 0.9 | 1.67 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.7 | 0.1 | 6 |
| ME/CFS with IBS | 0.2 | 0.4 | -1 |
| ME/CFS without IBS | 0.6 | 0.2 | 2 |
| Menopause | 0.6 | 0.6 | |
| Metabolic Syndrome | 2.6 | 1.9 | 0.37 |
| Mood Disorders | 3.4 | 1 | 2.4 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 0.5 | 1 | -1 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | 0 |
| Neuropathy (all types) | 0 | 0.2 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.4 | 0.25 |
| Obesity | 1.6 | 0.8 | 1 |
| obsessive-compulsive disorder | 2.8 | 0.8 | 2.5 |
| Osteoarthritis | 1.5 | 0.1 | 14 |
| Osteoporosis | 0.6 | 0.2 | 2 |
| pancreatic cancer | 0 | 0 | |
| Parkinson's Disease | 0.6 | 0.9 | -0.5 |
| Polycystic ovary syndrome | 0.6 | 0.3 | 1 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.1 | 0 |
| primary biliary cholangitis | 0.8 | -0.8 | |
| Psoriasis | 0.9 | 0.5 | 0.8 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 0.9 | 1 |
| Rosacea | 0.1 | 0.1 | 0 |
| Schizophrenia | 1.5 | 0.2 | 6.5 |
| scoliosis | 0.1 | 0.2 | -1 |
| Sjögren syndrome | 0.4 | 1.1 | -1.75 |
| Sleep Apnea | 0.4 | 0.3 | 0.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1 | 0.3 | 2.33 |
| Systemic Lupus Erythematosus | 1.5 | 0.1 | 14 |
| Tic Disorder | 0.1 | 0.2 | -1 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 1.5 | 0.1 | 14 |
| Type 2 Diabetes | 2.5 | 2.3 | 0.09 |
| Ulcerative colitis | 1.1 | 2.1 | -0.91 |
| Unhealthy Ageing | 1.9 | 0.1 | 18 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.